Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556202 | 1.00 | MAPT (0.61) | MAPTNOTUMSMN1; SMN2TP53LMNA | |
| SCHEMBL21152328 | 0.86 | NOTUM (0.72) | MAPTNOTUMSMN1; SMN2TP53LMNA | |
| SCHEMBL4583569 | 0.79 | TP53 (0.70) | NOTUMSMN1; SMN2TP53LMNAKMT2A | |
| SCHEMBL3369534 | 0.78 | NOTUM (0.60) | MAPTNOTUMSMN1; SMN2TP53LMNA | |
| SCHEMBL21150838 | 0.78 | NOTUM (0.63) | MAPTNOTUMSMN1; SMN2TP53LMNA | |
| SCHEMBL4581917 | 0.78 | NOTUM (0.60) | MAPTNOTUMSMN1; SMN2TP53LMNA | |
| SCHEMBL10627585 | 0.78 | NOTUM (0.60) | MAPTNOTUMSMN1; SMN2TP53LMNA | |
| SCHEMBL5168614 | 0.78 | NOTUM (0.60) | MAPTNOTUMSMN1; SMN2TP53LMNA | |
| SCHEMBL3819681 | 0.78 | NOTUM (0.61) | NOTUMSMN1; SMN2TP53LMNAKMT2A | |
| SCHEMBL3891046 | 0.78 | NOTUM (0.60) | MAPTNOTUMSMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| US-11993729-B2 | Chemical mechanical polishing composition | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | disclosed |
| EP-3714012-B1 | CHEMICAL MECHANICAL POLISHING COMPOSITION | BASF SE (DE) | 2023-01-11 | — | — | EP | disclosed |
| CN-114262350-A | Organometallic compound, light-emitting device including organometallic compound, and electronic apparatus including light-emitting device | 三星显示有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220085303-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-03-17 | — | — | US | disclosed |
| CN-107922787-B | Use of Chemical Mechanical Polishing (CMP) compositions for polishing cobalt-containing substrates | 巴斯夫欧洲公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210151696-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANOMETALLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-05-20 | — | — | US | disclosed |
| US-20210102093-A1 | USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES | BASF SE (DE) | 2021-04-08 | — | — | US | disclosed |
| US-10899945-B2 | Use of a chemical mechanical polishing (CMP) composition for polishing of cobalt comprising substrates | BASF SE (DE) | 2021-01-26 | — | — | US | disclosed |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2010-02-04 | — | — | US | disclosed |
| EP-1663204-A4 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1663204-A2 | C-KIT MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005020921-A2 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | MAPT 4370/4885NOTUM 3734/4885SMN1; SMN2 3206/4885 |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | MAPT 263/4885NOTUM 2759/4885SMN1; SMN2 1991/4885 |
| US-20220085303-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | GPX1, LAGE3, NFE2L2 | MAPT 2098/4885NOTUM 124/4885SMN1; SMN2 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.